Home » Topics » Conferences

Conferences
RSS

Na+ channel inhibitor as cardioprotectant

Nov. 1, 1996

Tyrosine kinase inhibitor for restenosis

Nov. 1, 1996

Nonpeptide NK1/NK2 antagonist identified by Merck & Co.

Nov. 1, 1996

NK1/NK2 antagonist research at Hoechst Marion Roussel

Nov. 1, 1996

Dual H1/NK1 antagonists as potential antiallergics

Nov. 1, 1996

Merck NK1 antagonist shows antiemetic activity in ferrets

Nov. 1, 1996

Third-generation ultrasound contrast agent from Sonus

Nov. 1, 1996

Prolonged treatment with Salagen Tablets not associated with tachyphylaxis

Nov. 1, 1996

Spotlight on NK1 antagonists

Nov. 1, 1996

Lanepitant in clinical trials for pain

Nov. 1, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.